Trend Following
(11)
▼
Momentum
(6)
▼
Volatility
(5)
▼
Pattern Recognition
(5)
▼
Mean Reversion
(4)
▼
Volume Based
(5)
▼
Advanced
(10)
▼
TNXP
$14.29
$
Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.
Next Earnings
2026-02-25
Beta
1.871
Average Volume
Market Cap
Last Dividend
CIK
0001430306
ISIN
US8902608392
CUSIP
890260839
CEO
Seth Lederman
Sector
Healthcare
Industry
Biotechnology
Full Time Employees
81
IPO Date
2012-05-10
Status
Active
Latest News
| Title | Headline | Publisher | Date |
|---|---|---|---|
| Tonix Pharmaceuticals Presented Phase 3 RESILIENT Data on TONMYA™ (Cyclobenzaprine HCl Sublingual Tablets) at the 2026 Non-Opioid Pain Therapeutics Summit | TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass metabolism, optimizing parent-drug exposure during sleep and decreasing levels of the persistent active metabolite Treatment was well tolerated with minimal effects on weight or blood pressure CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on TONMYA™, which was investigated as TNX-102 SL, at the 2026 Non-Opioid Pain Therapeutics Summit, on January 29, 2026, in Boston, Massachusetts. | GlobeNewsWire | 2026-01-30 07:00:00 |
| Tonix Pharmaceuticals to Present at Two Investor Conferences in January 2026 | BERKELEY HEIGHTS, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully integrated, commercial biotechnology company, announced today that Tonix management will present and host investor meetings at the following January 2026 investor conferences. | GlobeNewsWire | 2026-01-06 07:00:00 |
| Tonix Pharmaceuticals Announces Pricing of $20.0 Million Registered Direct Offering | CHATHAM, N.J., Dec. 29, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully-integrated commercial stage biotechnology company, today announced it has entered into a securities purchase agreement with Point72 for the purchase and sale of 615,025 shares of its common stock at an offering price of $16.26 per share and, in lieu of shares of common stock, pre-funded warrants to purchase up to an aggregate of 615,025 shares of common stock at a purchase price of $16.259 per pre-funded warrant, which equals the offering price per share of the common stock less the $0.001 per share exercise price of each pre-funded warrant. The closing of the offering is expected to take place on or about December 30, 2025, subject to the satisfaction of customary closing conditions. | GlobeNewsWire | 2025-12-29 07:57:00 |
| Tonix Pharmaceuticals Announces Program Updates on Phase 2/3-Ready Long-Acting Monoclonal Antibody (mAb) Designed for Seasonal Prevention of Lyme Disease (TNX-4800) | Exploring clinical development plan options including a controlled human infection model (CHIM) and a Phase 2/3 adaptive field study | GlobeNewsWire | 2025-12-29 07:45:00 |
| Tonix Pharmaceuticals (NASDAQ:TNXP) & Citius Pharmaceuticals (NASDAQ:CTXR) Head to Head Contrast | Citius Pharmaceuticals (NASDAQ: CTXR - Get Free Report) and Tonix Pharmaceuticals (NASDAQ: TNXP - Get Free Report) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership and earnings. Insider and Institutional Ownership 16.9% of Citius | Defense World | 2025-12-19 02:00:45 |
| Tonix Pharmaceuticals Announces Licensing TNX-4900, a Selective Sigma-1 Receptor Antagonist for Chronic Neuropathic Pain from Rutgers University | Non-opioid analgesic shows efficacy in several animal pain models, including diabetic and chemotherapy-induced neuropathic pain | GlobeNewsWire | 2025-12-16 07:00:00 |
| Tonix Pharmaceuticals Appoints Irina Ishak as General Counsel | Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry Ms. Ishak brings more than 25 years of corporate legal and strategic leadership experience in the life sciences industry | GlobeNewsWire | 2025-12-09 07:00:00 |
SEC Filings
| Type | Filing Date | Accepted Date | Link |
|---|---|---|---|
| 5 | 2026-02-17 | 2026-02-17 | View Filing |
| 8-K | 2026-02-03 | 2026-02-03 | View Filing |
| SC 13G/A | 2026-01-30 | 2026-01-30 | View Filing |
| SC 13G/A | 2026-01-21 | 2026-01-21 | View Filing |
| SC 13G | 2025-12-31 | 2025-12-31 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 424B5 | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-29 | 2025-12-29 | View Filing |
| 8-K | 2025-12-16 | 2025-12-16 | View Filing |
| 8-K | 2025-12-09 | 2025-12-09 | View Filing |
| 424B5 | 2025-11-21 | 2025-11-21 | View Filing |
| 8-K | 2025-11-21 | 2025-11-21 | View Filing |
| 8-K | 2025-11-18 | 2025-11-18 | View Filing |
| 8-K | 2025-11-17 | 2025-11-17 | View Filing |
| 10-Q | 2025-11-10 | 2025-11-10 | View Filing |
| 8-K | 2025-11-10 | 2025-11-10 | View Filing |
| SC 13G | 2025-10-31 | 2025-10-31 | View Filing |
| 8-K | 2025-10-27 | 2025-10-27 | View Filing |
| 8-K | 2025-10-22 | 2025-10-22 | View Filing |
| SC 13G/A | 2025-10-17 | 2025-10-17 | View Filing |
| 8-K | 2025-10-07 | 2025-10-07 | View Filing |
| 8-K | 2025-09-30 | 2025-09-30 | View Filing |
| 8-K | 2025-09-29 | 2025-09-29 | View Filing |
| 8-K | 2025-09-18 | 2025-09-18 | View Filing |
| 8-K | 2025-09-17 | 2025-09-17 | View Filing |
| EFFECT | 2025-09-05 | 2025-09-05 | View Filing |
| S-3/A | 2025-09-04 | 2025-09-04 | View Filing |
| 4 | 2025-08-21 | 2025-08-21 | View Filing |
| 4 | 2025-08-20 | 2025-08-20 | View Filing |
| 8-K | 2025-08-18 | 2025-08-18 | View Filing |
| 8-K | 2025-08-15 | 2025-08-15 | View Filing |
| 8-K | 2025-08-11 | 2025-08-11 | View Filing |
| 10-Q | 2025-08-11 | 2025-08-11 | View Filing |
| 8-K | 2025-07-25 | 2025-07-25 | View Filing |
| 8-K | 2025-07-21 | 2025-07-21 | View Filing |
| SC 13G | 2025-07-17 | 2025-07-17 | View Filing |
| 8-K | 2025-07-16 | 2025-07-16 | View Filing |
| 8-K | 2025-07-10 | 2025-07-10 | View Filing |
| 8-K | 2025-07-09 | 2025-07-09 | View Filing |
| 8-K | 2025-07-02 | 2025-07-02 | View Filing |
| 8-K | 2025-06-16 | 2025-06-16 | View Filing |
| 4 | 2025-06-13 | 2025-06-13 | View Filing |
| 3 | 2025-06-13 | 2025-06-13 | View Filing |
| 8-K | 2025-06-13 | 2025-06-13 | View Filing |
| S-3 | 2025-06-12 | 2025-06-11 | View Filing |
| 424B5 | 2025-06-11 | 2025-06-11 | View Filing |
| 424B5 | 2025-06-11 | 2025-06-11 | View Filing |
| 8-K | 2025-06-11 | 2025-06-11 | View Filing |
| S-8 | 2025-05-30 | 2025-05-30 | View Filing |
| 8-K | 2025-05-21 | 2025-05-21 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 4 | 2025-05-15 | 2025-05-15 | View Filing |
| 8-K | 2025-05-14 | 2025-05-14 | View Filing |
| 8-K | 2025-05-12 | 2025-05-12 | View Filing |
| 10-Q | 2025-05-12 | 2025-05-12 | View Filing |
| 8-K | 2025-05-08 | 2025-05-08 | View Filing |
| 8-K | 2025-04-29 | 2025-04-29 | View Filing |
| 8-K | 2025-04-25 | 2025-04-25 | View Filing |
| 8-K | 2025-04-24 | 2025-04-24 | View Filing |
| 8-K | 2025-04-09 | 2025-04-09 | View Filing |
| 8-K | 2025-04-01 | 2025-04-01 | View Filing |
| DEF 14A | 2025-03-31 | 2025-03-31 | View Filing |
| 8-K | 2025-03-24 | 2025-03-24 | View Filing |
| PRE 14A | 2025-03-21 | 2025-03-21 | View Filing |
| ARS | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-18 | 2025-03-18 | View Filing |
| 10-K | 2025-03-18 | 2025-03-18 | View Filing |
| 8-K | 2025-03-10 | 2025-03-10 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 8-K | 2025-03-04 | 2025-03-04 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-28 | 2025-02-28 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 4 | 2025-02-27 | 2025-02-27 | View Filing |
| 8-K | 2025-02-21 | 2025-02-21 | View Filing |
| 3 | 2025-02-18 | 2025-02-18 | View Filing |
| SC 13G/A | 2025-02-14 | 2025-02-14 | View Filing |
| 8-K | 2025-02-07 | 2025-02-07 | View Filing |
| 8-K | 2025-02-06 | 2025-02-06 | View Filing |
| 8-K | 2025-02-04 | 2025-02-04 | View Filing |
| 8-K | 2025-02-03 | 2025-02-03 | View Filing |
| 8-K | 2025-01-08 | 2025-01-08 | View Filing |
| SC 13G/A | 2025-01-03 | 2025-01-03 | View Filing |
| 8-K | 2024-12-23 | 2024-12-23 | View Filing |
| 8-K | 2024-12-20 | 2024-12-20 | View Filing |
| 424B5 | 2024-12-20 | 2024-12-20 | View Filing |
| 8-K | 2024-12-17 | 2024-12-17 | View Filing |
| S-8 | 2024-12-06 | 2024-12-06 | View Filing |
| 8-K/A | 2024-12-03 | 2024-12-03 | View Filing |
Algorithm Performance
Upgrade To Premium for Full Access
| Algorithm | Profit/Loss | Profit Factor | # Trades | Sharpe | Sortino | Efficiency |
|---|---|---|---|---|---|---|
| Volume Gap | 26.36% | 1.06 | 39 | 0.57 | 0.39 | 31.66 |
| Price Action Strategy | 18.12% | 0.84 | 8 | 0.62 | 0.46 | 23.42 |
| Neural Forcast | 14.41% | 1.13 | 20 | 0.46 | 1.15 | 23 |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxx | xxxxxxx% | xxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxx | xx | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | x |
| xxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxx | xxxxxx% | xxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxx |
| xxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxx | xxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxx% | x | x | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxx | xxxxxx% | xxxx | x | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | x | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxx |
| xxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxx | x% | x | x | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | x% | x | xx | x | x | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | x% | x | x | x | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | x | xxx |
| xxxxxxxxx | xxxxxxx% | x | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxx | xxxxxxx% | xxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | x | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxx | xx | xxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | xx | xxxxx | xxxxx | x |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxx | xxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | x |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxx | xxxxxxxx% | x | x | xxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxx% | xxxx | x | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxx |
| xxxxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | xx | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxxxxxxxxxxxxxxxx | xxxxxxxx% | xxxx | x | xxxxx | xxxxx | xxxxx |
| xxxxxxxxx | xxxxxxxx% | xxx | x | xxxxx | xxxxx | xxxxx |